Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V114 in Healthy Japanese Infants
NCT03848065Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection (3 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Solicited Injection-site Adverse Event, Percentage of Participants With a Solicited Systemic Adverse Event and 1 more. Started Apr 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03848065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848065.